KLF12: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: KLF12

NCBI ID: G11278

KLF12

KLF12: A Potential Drug Target for Cancer and Neurodegenerative Diseases

The KLF12 transcription factor, also known as AP-2rep, is a protein that plays a crucial role in gene expression and cell development. It is a member of the AP-2/EREBP family of transcription factors, which are known for their ability to repress gene expression in response to DNA damage. KLF12 is expressed in a wide range of tissues and cells, including muscle, liver, and brain, and has been shown to play a role in the development and progression of a number of diseases. As a result, KLF12 has potential as a drug target or biomarker for a variety of conditions.

The KLF12 transcription factor is composed of approximately 200 amino acid residues and has a calculated molecular weight of 21 kDa. It is expressed in a variety of tissues and cells, including muscle, liver, brain, and placenta. KLF12 is a nuclear protein, which means that it is localized to the nucleus of the cell where it functions as a transcription factor. It is also a DNA-binding protein, which means that it can interact with specific DNA sequences to regulate gene expression.

One of the defining features of KLF12 is its ability to repress gene expression in response to DNA damage. This is because KLF12 is a transcription factor that has been shown to interact with DNA-binding proteins, such as the double-stranded DNA-binding protein p53. When DNA is damaged, p53 is activated and can cause KLF12 to repress gene expression to prevent further damage. This is one of the ways in which KLF12 can help to protect the cell from the harmful effects of DNA damage.

In addition to its role in DNA damage repair, KLF12 has also been shown to play a role in the development and progression of a number of diseases. For example, KLF12 has been shown to be involved in the development of cancer, particularly breast cancer. Studies have shown that KLF12 is expressed in a variety of breast cancer cells and that it can promote the growth and survival of these cells. In addition, KLF12 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These studies suggest that KLF12 may be a useful target for the development of new therapies for these diseases.

As a potential drug target, KLF12 has the potential to be used to treat a wide range of conditions, including cancer and neurodegenerative diseases. For example, because KLF12 is involved in the development and progression of cancer, it may be a useful target for cancer therapies that target this protein. In addition, because KLF12 is involved in the development and progression of neurodegenerative diseases, it may be a useful target for therapies that target this protein and prevent or reverse the effects of these diseases.

In conclusion, the KLF12 transcription factor is a protein that plays a crucial role in gene expression and cell development. It is a member of the AP-2/EREBP family of transcription factors and has been shown to repress gene expression in response to DNA damage. KLF12 is expressed in a variety of tissues and cells and has the potential as a drug target or biomarker for a variety of conditions, including cancer and neurodegenerative diseases. Further research is needed to fully understand the role of KLF12 in these processes and to develop effective therapies for the treatment of these conditions.

Protein Name: KLF Transcription Factor 12

Functions: Confers strong transcriptional repression to the AP-2-alpha gene. Binds to a regulatory element (A32) in the AP-2-alpha gene promoter

The "KLF12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLF12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets